Open AccessComparison of Pioglitazone vs Glyburide in Early Heart Failure: Insights From a Randomized Controlled Study of Patients With Type 2 Diabetes and Mild Cardiac Disease
Author(s) -
Giles Thomas D.,
Elkayam Uri,
Bhattacharya Mondira,
Perez Alfonso,
Miller Alan B.
Publication year - 2010
Publication title -
congestive heart failure
Language(s) - English
Resource type - Journals
eISSN - 1751-7133
pISSN - 1527-5299
DOI - 10.1111/j.1751-7133.2010.00154.x
Subject(s) - pioglitazone , medicine , heart failure , cardiology , type 2 diabetes , cardiac function curve , clinical endpoint , diabetes mellitus , confidence interval , randomized controlled trial , endocrinology
Pioglitazone may cause fluid retention, a well‐known side effect of thiazolidinediones, and may exacerbate heart failure. Patients with type 2 diabetes and mild cardiac disease (New York Heart Association functional class I) received pioglitazone (n=151) or glyburide (n=149) for 1 year. The primary endpoint was change in distance covered in the 6‐minute walk test. Main secondary endpoints included comparison of cardiovascular mortality and morbidity, analysis of changes from baseline in cardiac structure and function by echocardiogram, and lipid panel. There was no significant treatment difference in the mean change from baseline in the 6‐minute walk test (−11.7 m [95% confidence interval, −29.79 to 6.42]). Cardiovascular mortality and morbidity were not significantly different between the treatment groups. Echocardiographic data suggested no significant deterioration in cardiac function with pioglitazone, although more heart failure (10 vs 7 patients), edema (21.2% vs 12.8%), and weight gain (2.56±4.62 kg vs 0.86±3.85 kg) were observed than with glyburide. Congest Heart Fail. 2010;16:111–117. © 2010 Wiley Periodicals, Inc.